



ID NOW™ INFLUENZA A & B 2 — MOLECULAR. IN MINUTES.™

THE FASTEST MOLECULAR FLU TEST¹

TRUSTED RESULTS DURING THE PATIENT ENCOUNTER

ID NOW™ Influenza A & B 2 provides results in **5–13 minutes²** to support a timely diagnosis and inform patient care.

- Accurate, rapid molecular flu test results
- Convenient single-swab testing option of COVID-19 and Influenza A & B based on clinical necessity
- CLIA-waived intuitive procedure allows for easy standardization across care settings



RAPID AND ACTIONABLE INFLUENZA RESULTS

TEST AND DIAGNOSE WITHOUT DELAY


Impact care during the patient encounter with the ID NOW™ Influenza A & B 2 test. Reliable molecular test results are available in minutes for timely and efficient clinical management and infection control decisions.



Positive results
in as early as
5 MINUTES

Negative results in
13 MINUTES

INCLUDE COVID-19 IN THE PATIENT WORKUP WHEN CLINICALLY NECESSARY USING A SINGLE SWAB



SIMPLIFIED COLLECTION

Run multiple tests with a single swab



DIAGNOSTIC STEWARDSHIP

Right tests at the right time for optimal care and fewer unnecessary tests



PATIENT SATISFACTION

Single swab patient experience, fast results to expedite diagnosis and treatment


*ID NOW™ Influenza A & B 2 test time to result when run in sequential workflow after ID NOW COVID-19 2.0 test (sold separately). ID NOW™ software update to version 7.1 required for sequential workflow capability.

UNCOMPROMISED MOLECULAR PERFORMANCE

ISOLATE AND TREAT WITH HIGHER CONFIDENCE

Molecular technologies – isothermal and PCR – provide highly sensitive test results. The ID NOW™ platform uses isothermal technology to provide molecular results faster than PCR with equivalent detection of Flu.

- Detects **significantly more true positives** than antigen tests,⁴ to help reduce unnecessary antibiotic usage



POINT-OF-CARE SETTINGS ARE **TIME SENSITIVE**



RAPID MOLECULAR FLU A & B TESTING IMPACTS CARE

Point of care rapid molecular influenza tests increase availability of results in time for clinical management and infection control decisions, with demonstrated improved outcomes.

CLINICAL OUTCOMES

Time to Treatment	↓	59.7% ⁶ (14 hours)
Antibiotic Use	↓	as much as 55% ^{6,7,8}
Antiviral Use	↑	133% ⁷
Hospital Acquired Influenza Infections	↓	as much as 51% ⁹

OPERATIONAL IMPROVEMENTS

Results Received During Patient Encounter	↑	126% ¹⁰ (82.9% vs 36.7%)
Ancillary Testing	↓	as much as 21% ¹¹
Hospitalizations	↓	as much as 78.2% ^{6,11}
Length of Stay (ED)	↓	20.7% ⁶ (2.7 hours)
Length of Stay (Hospital)	↓	29.1% ⁷

ID NOW™ RAPID MOLECULAR PLATFORM

CLIA WAIVED TO STANDARDIZE USE ACROSS CARE SETTINGS



- Minimal training with on-screen video-guided operation
- No complex sample handling or manual pipetting required
- Room temperature storage — run tests on demand, right out of the box
- Robust on-board software, and POC Link connectivity tool to enable streamlined remote software updates for ID NOW™ Instruments.

ID NOW™ RESPIRATORY ASSAY MENU

COVID-19 6–12 mins	Influenza A & B 5–13 mins ²	Strep A 2–6 mins ¹²	RSV ≤ 13 mins
------------------------------	--	--	-------------------------

THE POINT. IS CARE.

PRODUCT NAME	PRODUCT CODE	CPT® CODE†	MEDICARE RATE††
ID NOW™ INFLUENZA A & B 2 TEST KIT	427-000	87502	\$95.80
ID NOW™ COVID-19 2.0 TEST KIT	192-000	87635	\$51.31
ID NOW™ INFLUENZA A & B 2 CONTROL KIT	425-080		
ID NOW™ COVID-19 2.0 CONTROL KIT	192-080		
ID NOW™ INSTRUMENT	NAT-024		

With Add-on
Sequential
Workflow

CPT® CODE†
87636

MEDICARE
RATE††
\$142.63

Each test kit contains 24 tests, collection swabs and controls.



CONTACT YOUR LOCAL ABBOTT REPRESENTATIVE
OR VISIT **GLOBALPOINTOFCARE.ABBOTT**

†Providers with a CLIA Certificate of Waiver should use the QW modifier when appropriate.

††2024 Medicare Clinical Laboratory Fee Schedule.

Current Procedural Terminology (CPT®) code information and current Medicare allowable reimbursement rates available at www.codemap.com/abbottpoc. As a courtesy to its customers, Abbott provides the most accurate and up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage of payment for our products or reimburse customers for claims that are denied by third party payors.

1. ID NOW™ Rapid Test Times to Result Analysis (v1.0). 2. ID NOW™ Influenza A & B 2 clinical trial data, held on file. 3. CDC. Testing Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses are Co-circulating, updated Dec 6, 2023. <https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians.htm>. 4. Merckx J, Wali R, Schiller I, et al. Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-analysis. *Ann Intern Med*. 2017 Sep 19;167(6):394–409. 5. Medscape. Physician Compensation Report 2017, accessed May 2, 2023. <https://www.medscape.com/sites/public/physician-comp/2017>. 6. Martinot M, Greigert V, Gravier S, et al. Positive Impact of a Point-Of-Care Molecular Influenza Test in the Emergency Department During the 2017–2018 Seasonal Influenza Epidemic. *Open Forum Infect Dis*. 2019;6(7). 7. O'Connell S, Conlan C, Reidy M, et al. The impact of point-of-care testing for influenza A and B on patient flow and management in a medical assessment unit of a general hospital. *BMC Res Notes*. 2020;13(1):143. 8. Nardi S, Carolis L, Iannini R, et al. Usefulness of rapid molecular tests in pediatric respiratory tract infections. *Ital J Pediatr*. 2022 Feb 3;48(1):21. 9. Teoh TK, et al. Outcomes of point-of-care testing for influenza in the emergency department of a tertiary referral hospital in Ireland. *J Hosp Infect*. 2021 Apr;110:45–51. 10. Peaper DR, Branson B, Parwani V, et al. Clinical impact of rapid influenza PCR in the adult emergency department on patient management, ED length of stay, and nosocomial infection rate. *Influenza Other Respir Viruses*. 2021;15(2):254–261. 11. Trabattoni E, Le V, Pilms B, et al. Implementation of Alere i Influenza A & B point of care test for the diagnosis of influenza in an ED. *Am J Emerg Med*. 2018;36(6):916–21. 12. ID NOW™ Strep A 2 clinical trial data, held on file.

© 2024 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. CPT is a registered trademark of the American Medical Association. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. COL-00893-04 01/24

